Table 2.
additional studies considered for the calculation of the reduction of hookworm prevalence after preventive chemotherapy
| Country | Year | Drug | Number of people surveyed at baseline | Individuals with hookworm infection baseline – last follow-up |
Follow up (months) | Age group | PC frequency | Ref |
|---|---|---|---|---|---|---|---|---|
| Myanmar | 2004 2013 |
Alb | 1 000 | 6.5%- 0.3% | 84 | SAC | 2/year | 10, 11 |
| Bangladesh | 2005 2016 |
Alb | 792 | 20.4% - 7.7% | 60 | SAC | 2/year | 12, 13 |
| Lao | 2008 | Meb | 2 885 | 18.7% - 22.23% | 24 | SAC | 2/year | 14 |
| Tanzania | 2009 | Alb | 1 194 | 50.9% - 10.7% | 132 | SAC | 1/year | 15 |
| Viet Nam | 2013 | Alb | 389 | 86% - 12% | 12, 30, 54 | WCBA | 2/year | 16 |
| Cuba | 2014 | Meb | 268 | 44.4% - 18.7% | 36 | SAC | 2/year | 17 |
| Peru | 2016 | Meb | 816 | 4.2% - 3.09% | 12, 24 | SAC | 3/year | 18 |
| Kenya | 2016 | Alb | 21 432 | 14.4% - 2.3% | 36 | SAC | 1/year | 19 |
| Sri Lanka | 2000 | Meb | 177 | 72% - 8.8% | 12, 24, 36, 48, 72 | SAC | 1/year | 20 |
| Oman | 2001 | Alb | 860 | 40% - 0.6% | 12, 24, 36, 48, 60 | SAC | 1/year | 21 |
| Nepal | 2003 | Alb | 711 | 64.7% - 33.9% | 24 | SAC | 2/year | 22 |
| Seychelles | 2003 | Meb | 1058 | 6.3% - 1.5% | 24, 36, 60 | SAC | 2/year | 23 |
| India | 2004 | Alb, DEC | 325 | 5% - 5% | 24 | SAC | 2/year | 24 |
| Cambodia | 2006 | Meb | 50 | 57.8% - 13.5%* | 60 | SAC | 2/year | 25 |
| Ghana | 2006 | Alb | 1010 | 87% - 23% | 12, 24 | SAC | 2/year | 26 |
| Uganda | 2007 | Alb | 4351 | 50.9% - 10.7% | 12, 24 | SAC | 1/year | 27 |
| Zambia | 2013 | Alb, IVR | 490 | 7.8% - 1.9% | 12, 18 | SAC | 1/year | 28 |
Alb= albendazole; Meb= mebendazole; DEC=diethylcarbamazine; IVR= ivermectin, SAC = School aged children PC= preventive chemotherapy, WCBA=Women of Child bearing age
*
average of 7 different surveys